What is Codexis?
Headquartered in Redwood City, California, Codexis, Inc. operates as a leader in enzyme engineering, utilizing its proprietary CodeEvolver platform to discover and develop high-performance proteins. These engineered enzymes are instrumental in optimizing manufacturing yields, reducing waste, and lowering energy consumption across the pharmaceutical, biotherapeutic, and fine chemical industries. Beyond its core protein engineering capabilities, the company is actively expanding its footprint through the development of the ECO Synthesis platform, which is designed to facilitate the scalable, enzymatic production of RNAi therapeutics. This strategic focus positions Codexis as a vital partner for companies seeking to modernize their production processes through sustainable, high-efficiency chemical synthesis.
How much funding has Codexis raised?
Codexis has raised a total of $160M across 4 funding rounds:
Series D
$37M
Stock Offering
$78M
Stock Offering
$5M
Debt
$40M
Series D (2006): $37M with participation from Pequot Ventures, Chevron, Maxygen, Bio*One Capital, and CMEA Ventures
Stock Issuance/Offering (2010): $78M, investors not publicly disclosed
Stock Issuance/Offering (2019): $5M supported by Casdin Capital
Debt (2024): $40M featuring Innovatus Capital Partners
Key Investors in Codexis
Pequot Ventures
FirstMark is an early-stage venture capital firm headquartered in New York City that backs exceptional founders and provides a platform designed to accelerate growth through transformative access to networks, customers, and top talent.
CMEA Ventures
CMEA Capital is a San Francisco-based venture capital firm with a clear focus on life sciences, high technology, and energy and materials investments, targeting companies with cutting-edge, differentiated technology.
Casdin Capital
Casdin Capital, LLC brings a deep understanding, expertise, and long-term perspective to financing the next generation of life science innovation, with a specific focus on diagnostics and molecular information.
What's next for Codexis?
With the recent capital injection, Codexis is well-positioned to accelerate the commercialization of its ECO Synthesis platform and deepen its penetration into the high-growth RNAi therapeutics market. The company's strategic roadmap emphasizes the expansion of its therapeutic manufacturing capabilities, aiming to address the increasing demand for more sustainable and cost-effective production methods in the pharmaceutical sector. By continuing to refine its protein engineering technology, Codexis is poised to capture additional market share in molecular diagnostics and biotherapeutics, further solidifying its role as an essential enabler of next-generation medicine. The firm's focus remains on driving long-term value through technological differentiation and operational excellence in the complex landscape of modern drug manufacturing.
See full Codexis company page
